Abstract. P2Y 12 is a platelet receptor that is involved in ADP signal transduction and is an attractive target for antithrombotic drugs. The side effects of antithrombotic drugs are not pleasant for the patient, so research into the development of new antithrombotic agents is still necessary. Evaluation of absorption, distribution, metabolism, elimination, and the toxicity profile of candidate drugs is an important step in drug development. The aim of this study was to predict the potency of ferulic acid (FA) and its derivatives (FA1-24) as antiplatelet drugs by a docking study on the P2Y 12 receptor (PDB ID: 4PXZ) and their ADMET performance. The docking study was performed using Molegro Virtual Docker, version 5.5. ADMET prediction of FA was conducted using the pkCSM online tool. The results of the in silico study showed that FA-19 had the lowest MolDock score (MDS), which means that this compound is predicted to have the greatest activity. FA-19 is also predicted to be practically non-toxic. It is expected that FA-19 will have good intestinal absorption and is similarly distributed in the intestine and in the blood plasma. Its penetration in the bloodbrain barrier is moderate but does not inhibit the CYP2D6 and CYP3A4 enzymes.
Introduction
Cardiovascular diseases and strokes are major problems of morbidity and mortality in many countries, including Indonesia. In Indonesia, the prevalence of heart and blood vessel diseases continuously increases and the prevalence of coronary heart disease (CHD) in 2013 was 0.5%. Deaths caused by cardiovascular diseases, especially CHD and strokes, are predicted to increase up to 23.3 million by 2030 [1] .
P2Y 12 receptors play an important role in thrombus formation, i.e. in ADP signal transduction, and are an attractive target for antithrombotic drugs such as Prasugrel and Cangrelor [2] [3] [4] . The P2Y 12 receptor can be used as a therapeutic target and can be applied to molecular modeling and structure-activity relationship based drug design [5] . Unfortunately, the current antithrombotic drugs possess undesired side effects, such as bleeding and hemostasis problems. Therefore, research on drug design of new antiplatelet agents is important [6] .
Drug design is an attempt to improve existing drugs or compounds with specific pharmacological activity and is often described as a systematic elaboration process with the aim of obtaining new drugs with better activity and reducing any side effects that exist through molecular manipulation. The structural changes of a compound will alter the physicochemical properties of the compound, including its lipophilic, electronic and steric properties, which may cause changes in its biological activity [7, 8] .
One of the cinnamic acid derivatives, i.e. (E)-3-(4-hydroxy-2-methoxyphenyl) propenoic acid or ferulic acid (FA3), has been reported as an inhibitor of platelet aggregation through in vitro assay [9] . The mechanisms of ferulic acid in preventing platelet aggregation are: (1) inhibiting the [Ca 2+ ] channel on the cell membrane surface and interfering with phospholipase C in releasing [Ca 2+ ] to reduce the combination of ADP with P2Y 12 ; and (2) inhibiting the synthesis of TXA2, which can bind to TXA2R to activate platelets [10] . In an effort to obtain an effective and safe anti-platelet compound, an in silico assay of FA derivatives (FA1-24) was observed through a docking study on the P2Y 12 receptor (PDB ID: 4PXZ).
An in silico assay is conducted by docking a molecule to predict its activity with the selected target cell. Docking is an attempt to harmonize the ligand, a small molecule inside the target cell, which is a large protein molecule [11] . The results of the in silico test are in the form of bond energy values, or the Moldock score (MDS). The bond energy indicates the amount of energy required to form a bond between the ligand and the receptor. The lower the bonding energy, the more stable the bond. If the ligand bond with the receptor is stable, it can be predicted that the activity will be stronger [12] .
Besides measuring docking activity, one of the principle stages in drug design is the evaluation of the pharmacokinetic properties, i.e. the absorption, distribution, metabolism, elimination, and toxicity (ADMET), of the candidate drug [13] . ADMET analysis using an animal model is expensive, so we used molecular modeling in an effort to predict the chemical properties of the molecular chemistry, the pharmacokinetic properties (ADME), and the toxicity of the compounds [13, 14] .
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Material and Method
Receptor
The molecular structure of P2Y 12 receptors can be downloaded via a protein data bank site [15] . The P2Y 12 receptor with PDB ID: 4PXZ was selected, which contains a ligand (5-(6-amino-2-(methylthio)-9H-purine-9-yl) -3,4-dihydroxyte -trahydrofuran-2-yl)-methyl diphosphate code 6AD_1201[A].
Ligand
The structure of the ligands (FA1-24) was drawn using the 2D/3D ChemBio Draw Ultra software application, version 12 (Cambridge Soft) and then copied into the ChemBio 3D Ultra software application, version 12, to create the 3D structure and measure its minimum energy using MMFF94. This was then stored as mol2 {SYBYL2 (*.Mol2)}.
Validation of Docking Study
The validation of the docking study was performed by re-docking the ligand reference into an appropriate protein cavity. Re-docking is accepted if the root mean square value (RMSD) < 2.0 Aº.
Docking Study
The docking study of these compounds on the P2Y 12 receptor (4PXZ) was conducted using Molegro Virtual Docker, version 5. 
Prediction of ADME and Toxicity of Compounds
Prediction of the pharmacokinetic properties (ADME: absorption, distribution, metabolism, and excretion) and toxicity of the FA derivatives was performed using the pkCSM online tool, i.e. firstly the tested compounds and the comparative compound were drawn as 2D molecular structures with ChemBio Draw Ultra and copied into ChemBio 3D Ultra to create a 3D structure, and then stored as * .sdf file or * .pdb files. Secondly, all of the tested compounds and the comparative compound were translated into SMILES format using SMILES Translator Online Help [16] . In the SMILES format, the compounds were processed using the pkCSM online tool [17] to predict the ADME and the toxicity of the compounds. Also, the ProTox online tool [18] was used to predict oral rodent toxicity by determining the LD50 value and the classification of compound toxicity based on the Globally Harmonized System (GSH).
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Results and Discussion
Docking Study
Molecular docking was carried out to elevate and develop the pharmacological activity of the FA derivatives. To explain the mode of binding between the FA derivatives and human P2Y 12 receptor, docking studies were performed using the X-ray crystal structure of human P2Y 12 in complex with its full agonist onto PDB ID: 4PXZ.
The MolDock score is a differential evolution algorithm in the Molegro Virtual Docker program. The MDS, or E score , is the sum of E inter and E intra by Eq. (1), E inter is estimated by Eq. (2) and E intra is estimated by Eq. (3).
( 1 )
E inter is the ligand-receptor interaction energy, while E intra is the internal energy of the ligand. E PLP is calculated by two different parameters, i.e. the van der Waals interaction and the electrostatic interactions [19] .
The MDS of the FA derivatives (FA1-24) can be seen in Figure 1 . The MDS of the reference ligand (5-(6-amino-2-(methylthio)-9H-purine-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-methyldiphosphate, code 6AD_1202[A] is -187.880 kcal/mol, while its RMSD value is 1.87 A.
Based on the data presented in Figure 1 , all FA derivatives (FA4-24) apart from FA1 and FA2 have an MDS value lower than FA3 (ferulic acid), as is generally known. The structure modification of FA3 to FA2 through the demethylation of the methoxy moiety of FA3 to the hydroxyl moiety of FA2 decreased the molar refractivity (MR) and the MDS. The structure modification of FA3 to FA1 through hydrogenation of the vinylic double bond of FA3 also decreased the MDS. Therefore, it is concluded that the methoxy and the vinylic double bond are important moieties interacting with the P2Y 12 receptor.
Structure modification of the phenolic group of FA3 with the benzoyl-and substituted-benzoyl moieties (FA16-19) leads to different three-dimensional (3D) shapes of the compounds, so their interactions with the receptor are more effective, especially the steric interactions. Molecule FA19 ((E)-3-(3-methoxy-4-((4-methoxybenzoyl)oxy)phenyl)acrylic acid) had the lowest MDS, i.e. -159.804 kcal/mol, while molecule FA3 had MDS -111.140 kcal/mol.
Compound FA19 had the highest PSA (A2) value (Table 2) among the other derivatives, enabling greater receptor interaction. Therefore, it can be predicted that the bond between molecule FA19 and the P2Y 12 receptor as the target protein is more stable than for FA3. This bond is the strongest among the other derivatives. The P2Y 12 receptor responds to the ADP signal and participates in the inhibition of adenyl cyclase, Ca 2+ -dependent cell migration, regulation of cell morphology, and cellular aggregation. P2Y 12 must be stimulated for ADPinduced platelet aggregation to occur, which can be prevented by a substance that impartially inhibits the receptor. P2Y 12 has a specific tissue distribution, making it an important target for therapeutic intervention [2] so that the compound binding to the receptor will inhibit P2Y 12 In Figure 3 , the interaction between molecule 6AD_1201[A] and the P2Y 12 receptor can be seen. Hydrogen bonding interaction occurs between the phosphate groups of molecule 6AD_1201[A] and the amino acid residues, i.e. Arg93, Cys97, Ser101, Tyr105, Thr163, Cys175, His187, Lys280, Arg256, Tyr259. In addition, steric interactions of the adenosine moiety take place with the residues Asn191 and Val190. According to Figure 4 , the molecule FA3 compound has three hydrogen bonds with Hys187, Lys179, Ser156, Asn191 and Cys194. In addition, FA3 also has steric interaction with amino acid residues of the P2Y 12 receptor, i.e. Val102, Tyr105, Tyr109, Ser156, Asn159, Val190. Based on Figure 5 , there was a modification in the phenolic moiety of FA3 into the p-methoxybenzoyl moiety of FA19. This modification led to an increase of the interaction between the FA19 molecule and the amino acid residues in the P2Y 12 receptor. The carboxylate group of FA19 molecules has hydrogen bonds with the residues Val102, Ser101, and Phe106. In addition, the methoxy group posseses hydrogen bonds with residue Thr260. 
ADMET Profiles
Chemical databases contain hundreds of thousands of molecules that could be suitable ligands for a receptor. But, no matter how good the fit with the receptor, the candidate molecule is of no use if the absorption is poor or if the drug is excreted too slowly from the body. 2245 drugs from the World Drugs Index database were analyzed and it was concluded that a compound is more likely to have poor absorption or permeability if: the molecular weight exceeds 500; the calculated octanol/water partition coefficient (log P) exceeds +5; there are more than 5 H-bond donors (HBD) expressed as the sum of O-H and N-H groups; and there are more than 10 H-bond acceptors (HBA) expressed as the sum of N and O atoms. The above analysis is called the Lipinski Rules of Five because all values are multiples of five [20] .
The results of the in silico study of the physicochemical properties of the FA derivatives can be seen in Table 1 . Based on Table 1 , it can be seen that the molecular weight values of the ferulic acid derivatives (FA1-24) ranged from 180.159 to 332.739 (<500), the value of log of the octanol/water partition coefficient (log P) ranged from 1.20 to 3.67 (< 5), the amount of HBD ranged from 3 to 5 (≤ 5), and the amount of HBA ranged from 1 to 3 (< 10). This means that all derivatives meet the Lipinski Rules of Five [20] . Hence, it can be predicted that these FA derivative compounds will be easily absorbed and have high permeability.
Table 1 Prediction of
In Silico values of physicochemical properties of ferulic acid derivative compounds using pkCSM Online Tool.
Table 1 (cont.) Prediction of In
Silico values of physicochemical properties of ferulic acid derivative compounds using pkCSM Online Tool. BM = molecular weight; LogP = logarithm of octanol/water partition coefficient; MR = molar refractivity; Torsion = bond between rotating atoms (rotatable bond); HBA = hydrogen bond acceptors; HBD = hydrogen bond donors; PSA = polar surface activity. Skin permeability is an important consideration for improving drug efficacy that is particularly of interest in the development of transdermal drug delivery. A molecule will barely penetrate the skin if log Kp is more than -2.5 cm/h [21] . From Table 2 it can be seen that the skin permeability (Kp) of ferulic acid derivatives ranges from -2.678 to -2.992 cm/h (< -2.5). Therefore, it can be predicted that all derivatives have good skin penetrability.
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The Caco-2 cell line is composed of human epithelial colorectal adenocarcinoma cells. The Caco-2 monolayer of cells is widely used as an in vitro model of the human intestinal mucosa to predict the absorption of orally administered drugs by measuring the log of the evident permeability coefficient (log Papp; log cm/s). A compound is considered to have a high Caco-2 permeability if it has Papp > 8 x 106 cm/s. For the pkCSM predictive model, high Caco-2 permeability is translated into predicted log Papp values > 0.90 cm/s [21] .
From Table 2 it can be seen that the Caco-2 permeability value (log Papp) of the ferulic acid derivatives ranges from 0.228 to 1.415 cm/s, and there are 19 compounds with log Papp > 0.9 cm/s, so it can be predicted that the compounds have a high Caco-2 permeability. Five FA derivatives, FA1, FA8, FA22, FA23, and FA24, have log Papp < 0.9 cm/s, so it is predicted that these compounds have low Caco-2 permeability.
The volume of distribution (VD) is the calculated volume that the whole quantity of a medicine will be circulated at an equal level of blood plasma. The higher the VD is, the larger the amount of a drug is distributed to tissue rather than plasma. This model is established from the estimation of the steady-state volume of distribution (VDss), which is then revealed as log L/kg. According to Pires et al. [21] , VDss higher than 2.81 L/kg (log VDss > 0.45) is categorized as high, whereas VDss lower than 0.71 L/kg (log VDss < -0.15) is categorized as low [12] . From Table 3 it can be seen that the VDss values of the FA derivatives range from -1.186 to 0.037, and three compounds have a VDss value of < -0.15, i.e. FA18, FA19, and FA20, so it can be predicted that almost all derivatives of these compounds can be distributed evenly providing an equal level of blood plasma.
The blood-brain barrier (BBB) secures the brain from exogenous compounds. The ability of a drug to cross into the brain is an important parameter to consider for reducing side effects and toxicities or to improve the efficacy of drugs whose pharmacological activity is within the brain. The permeability of the blood-brain barrier is calculated in vivo as log BB, the logarithmic ratio of the brain-to-plasma drug concentration. Molecules are able to pass through the blood brain barrier promptly when log BB is higher than 0.3, but compounds with log BB smaller than -1 barely reach the brain [21] . From Table 2 it can be seen that the ranges of log BB value of the FA derivatives range from -0.732 to 0.129, which means greater than -1, so it can be predicted that all the derivatives are able to penetrate the blood-brain barrier moderately.
The permeability of the blood-surface area of the central nervous system (CNS) permeability (log PS) is a direct measurement that can be obtained from in situ brain perfusions with the compound directly injected into the carotid artery. This lacks systemic distribution effects that may distort brain penetration [21] .
Compounds with log PS > -2 are considered to be able to penetrate the CNS, while those with log PS < -3 are considered to be unable to penetrate the CNS [21] . From Table 2 it can be seen that the log PS values of the FA derivatives range from -1.671 to -3.177. There is one compound (FA7, log PS = -1.617) capable of penetrating the CNS, one compound (FA23, Log PS = -3.177) that is unable to penetrate the CNS, while the other derivatives are able to penetrate the CNS moderately.
Cytochrome P450 is an important detoxification enzyme in the body, mainly found in the liver. It oxidizes xenobiotics to facilitate their excretion. Many drugs are deactivated by cytochrome P450's but some can be activated by it. Inhibitors of this enzyme, such as grapefruit juice, can affect drug metabolism and are contraindicated. The cytochrome P450's are responsible for the metabolism of many drugs. However, inhibitors of the P450's can dramatically alter the pharmacokinetics of these drugs, so it is important to evaluate whether a given compound is likely to be a cytochrome P450 substrate. The two main isoforms responsible for drug metabolism are P2D6 cytochrome (CYP2D6) and P3A4 cytochrome (CYP3A4) [21] . From Table 2 it can be seen that almost all ferulic acid derivatives do not affect or inhibit the CYP2D6 and CYP3A4 enzymes, except the FA20 and FA21 compounds, which can affect the CYP3A4 enzyme, so it can be predicted that the derivatives tend to be metabolized by the P450 enzymes in the body.
Organic cation transporter 2 (OCT2) is a protein transporter that has a vital contribution in renal uptake, disposition, and clearance of drugs and endogenous compounds. OCT2 substrates have potential for adverse interactions with codirected OCT2 inhibitors. Evaluating the transfer of a candidate compound by OCT2 offers useful information regarding not only its clearance but also potential contraindications [21] . From Table 2 it can be seen that not all FA derivatives affect the OCT2 substrate, so it can be predicted that the derived compounds are not OCT2 substrates.
A steady-state level is reached when the drug is bioavailable and administrated at the appropriate dosing rate. Both of these are dependent on drug clearance, which can be determined from the total of hepatic (metabolism in the liver and biliary clearance) and renal clearance (excretion via the kidneys). The higher the CLTOT value of the compound, the faster the excretion process [21] . From Table 2 it can be seen that the log CLTOT value of the ferulic acid derivatives ranges from -0.070 to 0.800 ml/min/kg and from these values the rate of excretion of the compound can be predicted.
Determining the toxicity of the compound can be done by the Ames toxicity test. The Ames test is a method to predict the mutagenic potential of a compound using bacteria. A positive test indicates that the compound is mutagenic and therefore may act as a carcinogen [21] . From Table 2 it can be seen that seven FA derivatives, FA2, FA3, FA4, F9, FA10, FA13, and FA23, are predicted to have mutagenic effects.
Another toxicity test is the hepatotoxicity test. One of the most concerning safety aspects in drug development research is drug-induced liver injury, which also increases the drug attrition rate. The compound that showed at least one pathological or physiological hepatic event was considered hepatotoxic and highly related to liver disruption. From Table 2 it can be seen that almost all of the ferulic acid derivatives are not hepatotoxic. Only one compound (FA-21) is predicted to induce hepatotoxic effects.
The potential toxicity of a prospective compound has to be assessed. The acute toxicity and relative toxicity of different compounds can be determined from the lethal dosage value. To complement the toxicity prediction of ferulic acid derivatives there is an acute oral toxicity test for rodents (LD50) and an acute toxicity classification of compounds based on the Globally Harmonized System (GSH) using the Protox online tool. From Table 2 it can be seen that the prediction for the LD50 values of the ferulic acid derivatives range from 300 to 9600 mg/kg, which means that they are included in toxicity classes from GSH Tables 3-6, i.e. the compounds have toxicity indications ranging from 'has harmful effects when swallowed' to 'is not toxic' ( Table 2 ).
There are three FA derivatives that belong to category 3 GSH (LD50 = > 50 ≤ 300 mg/kg), i.e. FA20, FA21, FA22, which means that those compounds have toxic effects when swallowed, and three compounds belong to category 6 GSH (LD50 = > 5000 mg/kg), i.e. FA6, FA7, and FA8, which means that they are not toxic. Eight compounds belong to category 5 (LD50 = > 2000 ≤ 5000 mg/kg), i.e. FA2, FA10, FA14-19, which means that these compounds have relatively low acute toxicity. The other nine compounds belong to category 4, which means they are slightly toxic.
Physicochemical-ADMET Properties Relationships
Based on the regression analysis performed between the in silico activities on the P2Y 12 receptor (MDS, Figure 1 ) with each physicochemical property, i.e. Log P, MR, and E total , shown in Table 1 , some linear relationships were found between the in silico activity on the P2Y 12 The equation that showed the highest significance was the relationship between MDS and combined MR-E total , denoted by Eq. (6) (P < 0.05, adjusted R 2 = 0.735, and F = 32.901). However, the coefficients of each physicochemical variable in the regression equations were negative, indicating unfavorable relationships. The addition of Log P or E total in the regression equations containing molar refractivity decreased the significance (F value) and the coefficient of each physicochemical variable was still negative.
The combination of three physicochemical variables in one equation also decreased the significance (F value) but gave a positive variable coefficient for Log P. These results indicate that the physicochemical properties (Log P, MR, and E total ) will contribute positively to ligand-receptor interactions when combined.
Conclusion
From this study it was concluded that all FA derivatives have good ADMET profiles, except three derivatives that are harmful when swallowed. Compound FA19 has the greatest activity as antiplatelet agent based on its interaction with the P2Y 12 receptor.
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